BLK
ENSG00000136573
Target class
Kinase
Chromosome
8
Approved drugs
1
Clinical candidates (approved and in development)
5
- Approved drugs
- 1
- ClinGen gene-disease validity
- Refuted
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Other names
- MGC10442
- Target name
- BLK
- Gene name
- BLK proto-oncogene, Src family tyrosine kinase
- Gene symbol
- BLK
- Protein name
- Tyrosine-protein kinase Blk (EC 2.7.10.2) (B lymphocyte kinase) (p55-Blk)
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 6
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 103.76
- Tissue specificity (Gini)
- 0.933
- Tissue specificity (tau)
- 0.977
- KEGG gene identifiers
- hsa:640
- Protein interaction confidence
- 0.807211
- Protein interaction partners
- 19
- R-HSA-8939245
- R-HSA-983695
- End position
- 11564599
- Start position
- 11486894
- Chromosome
- 8
- Strand
- Forward
- Cell membrane
- Lipid-anchor . Note=Present and active in lipid rafts. Membrane location is required for the phosphorylation of CD79A and CD79B (By similarity). .
- Tissue specificity (tau)
- 0.977215
- Expression inequality (Gini)
- 0.933158
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 103.76
- Spleen
- 82.08
- Small Intestine - Terminal Ileum
- 25.48
- Whole Blood
- 6.58
- Lung
- 1.44
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes103.76
- Spleen82.08
- Small Intestine - Terminal Ileum25.48
- Whole Blood6.58
- Lung1.44
- Colon - Transverse1.25
- Stomach0.72
- Esophagus - Mucosa0.72
- Minor Salivary Gland0.63
- Fallopian Tube0.55
- Liver0.54
- Kidney - Cortex0.49
- Thyroid0.45
- Cells - Cultured fibroblasts0.45
- Testis0.4
- Kidney - Medulla0.33
- Adipose - Visceral (Omentum)0.29
- Prostate0.26
- Breast - Mammary Tissue0.22
- Adipose - Subcutaneous0.18
- Bladder0.17
- Vagina0.17
- Cervix - Endocervix0.15
- Artery - Coronary0.15
- Adrenal Gland0.14
And 29 more, listed on the interactive page.
- GO:0018108
- GO:0032024
- GO:0035556
- GO:0050853
Cellular components
- GO:0005829
- GO:0004713
- GO:0004715
- GO:0005515
Related records
Trials (878)
- A Bioequivalence Study of Dasatinib Tablet
- A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
- A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
- A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Drugs (14)
- Acalabrutinib
- CEP-11981
- Dasatinib
- Dasatinib anhydrous SRC inhibitor
- Dasatinib laurylsulfate SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ibrutinib
- Ilorasertib SRC inhibitor
- JNJ-64264681
- Nemtabrutinib
- TG100-801 SRC inhibitor
- Tirabrutinib
- Tirabrutinib hydrochloride
- XL-228 SRC inhibitor